NUVB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NUVB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nuvation Bio's annualized ROCE % for the quarter that ended in Dec. 2023 was -13.63%.
The historical data trend for Nuvation Bio's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
ROCE % | -20.23 | -19.15 | -16.89 | -15.76 |
Nuvation Bio Quarterly Data | ||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
ROCE % | Get a 7-Day Free Trial | -14.62 | -16.28 | -16.43 | -16.96 | -13.63 |
Nuvation Bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -99.822 | / | ( ( (672.141 - 13.161) | + | (621.484 - 13.974) ) | / 2 ) | |
= | -99.822 | / | ( (658.98 | + | 607.51) | / 2 ) | |
= | -99.822 | / | 633.245 | ||||
= | -15.76 % |
Nuvation Bio's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | -83.324 | / | ( ( (630.87 - 16.143) | + | (621.484 - 13.974) ) | / 2 ) | |
= | -83.324 | / | ( ( 614.727 | + | 607.51 ) | / 2 ) | |
= | -83.324 | / | 611.1185 | ||||
= | -13.63 % |
(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NYSE:NUVB) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Nuvation Bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Oleg Nodelman | director | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Biotech Opportunity Gp, Llc | director | 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558 |
Ecor1 Venture Opportunity Fund, Lp | director | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Ecor1 Capital Fund, L.p. | director | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Ecor1 Capital, Llc | director | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Ecor1 Capital Fund Qualified, L.p. | director | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Kathryn E Falberg | director | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Dongfang Liu | officer: Chief Medical Officer | C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 401, NEW YORK NY 10036 |
Omega Fund V Gp, L.p. | 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
Omega Fund Iv Gp, L.p. | 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
Omega Fund V, L.p. | 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
Omega Fund V Gp Manager, Ltd. | 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
David C. Hanley | officer: Chief Technical Operations | C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036 |
Daniel G Welch | director | 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707 |
Kim D Blickenstaff | director | C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105 |
From GuruFocus
By Business Wire Business Wire • 06-27-2022
By Business Wire Business Wire • 08-01-2022
By Business Wire Business Wire • 05-09-2022
By PRNewswire PRNewswire • 07-09-2022
By Business Wire Business Wire • 07-18-2022
By Sydnee Gatewood • 09-23-2022
By Business Wire Business Wire • 06-01-2023
By Business Wire Business Wire • 05-04-2023
By PurpleRose PurpleRose • 07-15-2022
By GuruFocus Research • 11-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.